VITAL STATS: BCM-95, a patented high bioavailability curcumin, DolCas Biotech, LLC
STUDY CLAIM: BCM-95 curcumin was found to be equal to the prescription rheumatoid arthritis drug, diclofenac sodium, but with fewer adverse effects, in a clinical study of rheumatoid arthritis.
PUBLISHED: Chandran, B. and Goel, A. (2012), A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis. Phytother. Res.. doi: 10.1002/ptr.4639
ABSTRACT: The study followed 45 subjects, randomized to three groups, for 8 weeks. Group one received diclofenac sodium, 50 mg, twice daily; group two received 500 mg BCM-95 high absorption curcumin twice daily; and group three received both diclofenac sodium and BCM-95 curcumin. In the BCM-95 curcumin groups, there were no drop outs due to adverse effects, but in the diclofenac sodium (NSAID) group, 14 percent withdrew due to adverse effects.
All study participants had diagnosed rheumatoid arthritis, functional class I or II. Laboratory studies on kidney and liver function, blood sugar, and a complete blood count were performed before and after participation. There were no significant changes in these measurements in general in all the groups. One laboratory analysis adverse event was reported in the drug (diclofenac sodium) group.
In the Disease Activity Score (DAS)28 assessment which includes assessments of joint swelling and pain, BCM-95 curcumin had the highest impact for reducing disease symptoms, followed by BCM-95 curcumin with diclofenac sodium, with the diclofenac sodium-alone group third. However, though the numbers were higher in the BCM-95 group, none of the differences between the drug and curcumin group were statistically significant as for effectiveness. But curcumin treatment was superior in terms of safety and tolerability.
The BCM-95 group showed improvement over others in reducing C-reactive protein (CRP) a measure of chronic inflammation, and antistreptococcal antibodies (ASO) titers, which are associated with severity of RA activity.
POTENTIAL APPLICATIONS: best delivered as dietary supplement in tablet or capsule form for support of healthy inflammation response.
SoyLife soy isoflavones—Frutarom
VITAL STATS: SoyLife soy isoflavones from Frutarom and ARTICOA chocolate from Barry Callebaut
STUDY CLAIM: Cacao-flavonoids and soy isoflavones can significantly improve biomarkers of CVD risk in postmenopausal women with type 2 diabetes
PUBLISHED: Curtis P. J. et al, Chronic Ingestion of Flavan-3-ols and Isoflavones Improves Insulin Sensitivity and Lipoprotein Status and Attenuates Estimated 10-Year CVD Risk in Medicated Postmenopausal Women With Type 2 Diabetes, Diabetes Care 2012, 35, 226 – 232.
ABSTRACT: Despite being medicated, patients with type 2 diabetes have elevated CVD risk, particularly postmenopausal women. Although dietary flavonoids have been shown to reduce CVD risk factors in healthy participants, no long-term trials have examined the additional benefits of flavonoids to CVD risk in medicated postmenopausal women with type 2 diabetes. The clinical trial consisted of 93 medicated postmenopausal women with type 2 diabetes. Subjects were randomly allocated to consume 27 g/day (split dose) of flavonoid-enriched chocolate (Barry Callebaut ACTICOA™ chocolate containing 850 mg flavan-3-ols [90 mg epicatechin] and 100 mg of isoflavones [aglycone equivalents)]/day) or a matched placebo for one year.
Adherence was high (flavonoid 91.3%; placebo 91.6%). Compared with the placebo group, the combined flavonoid intervention resulted in a significant reduction in estimated peripheral insulin resistance and improvement in insulin sensitivity as a result of a significant decrease in insulin levels. Significant reductions in total cholesterol: HDL-cholesterol (HDL-C) ratio (-0.2 ± 0.1; P = 0.01) and LDL-cholesterol (LDL-C) (-0.1 ± 0.1 mmol/L; P = 0.04) were also observed. Estimated 10-year total coronary heart disease risk (derived from UK Prospective Diabetes Study algorithm) was attenuated after flavonoid intervention (flavonoid +0.1 ± 0.3 vs. placebo 1.1 ± 0.3; P = 0.02). No effect on blood pressure, HbA(1c), or glucose was observed.
One-year intervention with flavan-3-ols and isoflavones improved biomarkers of CVD risk, highlighting the additional benefit of flavonoids to standard drug therapy in managing CVD risk in postmenopausal type 2 diabetic patients.
POTENTIAL APPLICATIONS: SoyLife is available in concentrations ranging from 3 percent to 40 percent and can be used in tablets, capsules, soft-gel capsules, as well as multiple functional food and beverage applications.